Use of cultivated osteoprogenitor cells to increase bone formation in segmental mandibular defects: an experimental pilot study in sheep

2001 ◽  
Vol 30 (6) ◽  
pp. 531-537 ◽  
Author(s):  
H. Schliephake ◽  
J.W. Knebel ◽  
M. Aufderheide ◽  
M. Tauscher
Keyword(s):  
Pilot Study ◽  
Bone Formation ◽  
Osteoprogenitor Cells ◽  
Increase Bone Formation

scholarly journals Graphene-Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization

2017 ◽  
Vol 5 (2) ◽  
pp. 1700578 ◽  
Author(s):  
Ce Dou ◽  
Ning Ding ◽  
Fei Luo ◽  
Tianyong Hou ◽  
Zhen Cao ◽  
...  
Keyword(s):  
Bone Formation ◽  
Increase Bone Formation

scholarly journals Development of cyclic peptides with potent in vivo osteogenic activity through RaPID-based affinity maturation

2020 ◽  
Vol 117 (49) ◽  
pp. 31070-31077 ◽  
Author(s):  
Nasir K. Bashiruddin ◽  
Mikihito Hayashi ◽  
Masanobu Nagano ◽  
Yan Wu ◽  
Yukiko Matsunaga ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Cyclic Peptides ◽  
Treatment Options ◽  
Affinity Maturation ◽  
Great Promise ◽  
Anabolic Activity ◽  
Anabolic Treatment ◽  
Increase Bone Formation

Osteoporosis is caused by a disequilibrium between bone resorption and bone formation. Therapeutics for osteoporosis can be divided into antiresorptives that suppress bone resorption and anabolics which increase bone formation. Currently, the only anabolic treatment options are parathyroid hormone mimetics or an anti-sclerostin monoclonal antibody. With the current global increases in demographics at risk for osteoporosis, development of therapeutics that elicit anabolic activity through alternative mechanisms is imperative. Blockade of the PlexinB1 and Semaphorin4D interaction on osteoblasts has been shown to be a promising mechanism to increase bone formation. Here we report the discovery of cyclic peptides by a novel RaPID (Random nonstandard Peptides Integrated Discovery) system-based affinity maturation methodology that generated the peptide PB1m6A9 which binds with high affinity to both human and mouse PlexinB1. The chemically dimerized peptide, PB1d6A9, showed potent inhibition of PlexinB1 signaling in mouse primary osteoblast cultures, resulting in significant enhancement of bone formation even compared to non-Semaphorin4D–treated controls. This high anabolic activity was also observed in vivo when the lipidated PB1d6A9 (PB1d6A9-Pal) was intravenously administered once weekly to ovariectomized mice, leading to complete rescue of bone loss. The potent osteogenic properties of this peptide shows great promise as an addition to the current anabolic treatment options for bone diseases such as osteoporosis.

Sex steroids and the rate of new bone formation in iliac grafts: a prospective clinical pilot study

2020 ◽  
Vol 31 (S20) ◽  
pp. 48-48
Author(s):  
Julia Half ◽  
Claudia Sachse ◽  
Kajta Nelson ◽  
Max Heiland ◽  
Susanne Nahles
Keyword(s):  
Pilot Study ◽  
Bone Formation ◽  
Sex Steroids ◽  
New Bone Formation

Mechanisms of ectopic bone formation by human osteoprogenitor cells on CaP biomaterial carriers

Biomaterials ◽  
2012 ◽  
Vol 33 (11) ◽  
pp. 3127-3142 ◽  
Author(s):  
Yoke Chin Chai ◽  
Scott J. Roberts ◽  
Eline Desmet ◽  
Greet Kerckhofs ◽  
Nick van Gastel ◽  
...  
Keyword(s):  
Bone Formation ◽  
Ectopic Bone Formation ◽  
Osteoprogenitor Cells ◽  
Ectopic Bone

High Dose Simvastatin Has No Beneficial Effect on Markers of Bone Turn-Over in Multiple Myeloma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4824-4824
Author(s):  
Teis E. Sondergaard ◽  
Per T. Pedersen ◽  
Thomas L. Andersen ◽  
Thomas Lund ◽  
Patrick Garnero ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Pilot Study ◽  
Bone Resorption ◽  
Bone Formation ◽  
High Dose ◽  
Osteoclast Activity ◽  
Bone Formation Markers ◽  
Bone Degradation ◽  
Activity Trap

Abstract Background: Bone degradation in multiple myeloma (MM) is a result of increased bone degradation by osteoclasts that is not compensated for by bone forming osteoblasts. Ideally new drugs used for treatment of MM should target not only the myeloma cells but also the imbalance between bone resorption and bone formation. Statins have been shown to inhibit myeloma cell proliferation and induce apoptosis in vitro. Furthermore statins have been shown to stimulate osteoblasts and inhibit osteoclasts both in vitro and in animal models. Statins are normally used at doses around 20–80 mg/day, but in order to reach serum concentrations that can match the in vitro experiments MM patients were treated with 15 mg/kg/day of Simvastatin (HD-Sim) divided in two daily doses in this study. This high dose has previously been found to be safe for MM patients (Haematologica 2006, 91,542–545) Patients and methods: Six patients with advanced MM have been included in this pilot study, 4 males and 2 females with an average age of 68 years and an average duration of disease of 43 months. The patients were treated with 2 cycles of HD-Sim for seven days followed by a break of 21 days in a 4-weeks cycle. Two of the patients were treated with bisphosphonates during the study, and 4 had previously been treated with bisphosphonates. Endpoints are change in concentrations of markers of osteoclast activity (TRAP) or bone resorption (CTX, NTX, ICTP) or markers of bone formation (Osteocalcin and PINP). Cholesterol, OPG and DDK-1 were also measured. Results: Two patients completed the protocol with two cycles of HD-Sim at full dose, 2 patients were reduced to 7.5 mg/kg/day simvastatin in cycle 2 due to nausea and diarrhea and 2 patients left the protocol after 3 weeks (deaths not related to high dose simvastatin). All patients experienced gastrointestinal toxicity grade 1–2. Myalgia and other muscular symptoms grade 1–2 were reported by 5 patients but were not associated with an increase in creatin kinase. TRAP and NTX activity in serum increased for all 6 patients during the seven days of treatment with HD-Sim indicating that bone resorption may have been stimulated rather than inhibited. The other markers of bone resorption and the bone formation markers showed no change. All patients responded with a significantly reduced level of cholesterol in serum. None of the patients showed any reduction in free monoclonal light chains or monoclonal proteins in serum during treatment with HD-Sim and 2 of the 4 patients completing the protocol showed progression of diseases. Conclusion: This pilot study of HD-Sim in advanced MM has been terminated due to lack of response and evidence from two markers of osteoclast activity (TRAP) and bone resorption (NTX) that HD-Sim may be harmful rather than beneficial in MM.

A 5% Increase in Trabecular (Spine) Bone Density Occurs in the First Six Months after Weaning (Factors Affecting Bone Formation after Breastfeeding Pilot Study [FABB-Pilot])

2016 ◽  
Vol 40 (5) ◽  
pp. S2
Author(s):  
Sandra Cooke-Hubley ◽  
Beth J. Kirby ◽  
Chrissy Wells ◽  
Gerry Mugford ◽  
James Valcour ◽  
...  
Keyword(s):  
Pilot Study ◽  
Bone Density ◽  
Bone Formation ◽  
Factors Affecting

Collagen/glycosaminoglycan coatings enhance new bone formation in a critical size bone defect — A pilot study in rats

2017 ◽  
Vol 71 ◽  
pp. 84-92 ◽  
Author(s):  
Yvonne Förster ◽  
Ricardo Bernhardt ◽  
Vera Hintze ◽  
Stephanie Möller ◽  
Matthias Schnabelrauch ◽  
...  
Keyword(s):  
Pilot Study ◽  
Bone Formation ◽  
Bone Defect ◽  
Critical Size ◽  
New Bone Formation

Nonprocessed Adipose Tissue Graft in the Treatment of Peri-Implant Osseous Defects in the Rabbit's Tibiae: A Pilot Study

2014 ◽  
Vol 40 (1) ◽  
pp. 60-66
Author(s):  
Diogo Godoy Zanicotti ◽  
Fernanda Brugin Matsubara ◽  
João César Zielak ◽  
Allan Fernando Giovanini ◽  
Cícero de Andrade Urban ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Pilot Study ◽  
Bone Formation ◽  
Dental Implants ◽  
New Technique ◽  
Tissue Graft ◽  
Bone To Implant Contact ◽  
A New Technique ◽  
Osseous Defect ◽  
Osseous Defects

We hypothesized that a new technique using nonprocessed adipose tissue could regenerate bone around dental implants. Eighteen rabbits received 1 implant per tibia surrounded by a surgically created osseous defect. The defects were assigned for treatment into 3 groups: C, AT, and AB. The percentages of bone-to-implant contact were 17.64% ± 16.22% (AB), 3.54% ± 7.08% (AT), and 12.71% ± 10.11% (C) (ρ = 0.25). The use of adipose tissue around surgically created peri-implant osseous defects interferes with bone formation.

Sign in / Sign up

Export Citation Format

Share Document